| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/19/2008 | WO2007038678A8 Analogs of ghrelin |
| 06/19/2008 | US20080147199 Tissue scaffold having aligned fibrils, apparatus and method for producing the same, and artificial tissue and methods of use thereof |
| 06/19/2008 | US20080147169 Rgd peptide attached to bioabsorbable stents |
| 06/19/2008 | US20080147077 Protein stabilization formulations |
| 06/19/2008 | US20080147065 Flowable carrier compositions and methods of use |
| 06/19/2008 | US20080147045 Use of VEGF-C or VEGF-D in Reconstructive Surgery |
| 06/19/2008 | US20080146808 Antiapoptosis; cancers; inhibiting the caspases; |
| 06/19/2008 | US20080146781 Modified Human Four Helical Bundle Polypeptides and Their Uses |
| 06/19/2008 | US20080146779 Novel Melanocortin Receptor Templates, Peptides, and Use Thereof |
| 06/19/2008 | US20080146639 Reducing the incidence of fibrosis by the co-administration of effective amounts of telmisartan and ramipril; strokes; cardiovascular disorders; organoprotective, tissue-protective, and vasculoprotective effects of combined treatment |
| 06/19/2008 | US20080146513 Synthetic Ion Channels |
| 06/19/2008 | US20080146512 cell cycle control by administering opioid growth factor (OGF), which activates opioid growth factor receptor (OGFr) signaling. , the present invention provides a method for monitoring OGF modulation or treatment of a cell proliferation or growth related condition in a subject by assessing the kinase |
| 06/19/2008 | US20080146511 method of peptides, peptides, method and kit for the identification of infections by Mycobacterium leprae, as well as to pharmaceutical and immunological compositions containing as active principle(s), peptide(s) of Mycobacterium leprae or sequences functionally similar |
| 06/19/2008 | US20080146510 For suppressing cell proliferation/tumor growth or modulating immune system by transformation of T-lymphocytes or enhancement of natural killer cells |
| 06/19/2008 | US20080146509 delivery agent, parathyroid hormone, and calcitonin. This composition exhibits increased delivery of parathyroid hormone and/or calcitonin and is useful for the treatment of osteoporosis. The composition also permits simultaneous oral delivery of parathyroid hormone and calcitonin |
| 06/19/2008 | US20080146508 Soluble cyclic analogues of beta amyloid peptide |
| 06/19/2008 | US20080146507 Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor |
| 06/19/2008 | US20080146506 Methods of Suppressing Microglial Activation |
| 06/19/2008 | US20080146505 47 Human Secreted Proteins |
| 06/19/2008 | US20080146504 Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
| 06/19/2008 | US20080146503 albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins |
| 06/19/2008 | US20080146502 method for modulating the sensation of satiety perception and to agents useful for same. Such agents are useful in modulating, controlling or otherwise affecting inter alia obesity, anorexia, weight maintenance, metabolic energy levels and/or inflammatory conditions in a subject |
| 06/19/2008 | US20080146501 identifying a subject at risk for developing AMD are disclosed. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material. Therapeutic compositions and methods are also provided for delaying the progression or onset of the development |
| 06/19/2008 | US20080146500 encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. |
| 06/19/2008 | US20080146499 Identification of the Precise Amino Acid Sequence of the Epitope Recognized by the Potent Neutralizing Human Anti-Hiv-1 Monoclonal Antibody Igg1b12 |
| 06/19/2008 | US20080146498 Diagnostic Agent For Ischemic Heart Disease Risk Group |
| 06/19/2008 | US20080146497 therapeutic methods, compositions, and medicaments related to cyclosporine. |
| 06/19/2008 | US20080146496 Novel Melanocortin Receptor Templates, Peptides, and Use Thereof |
| 06/19/2008 | US20080146495 methods for inhibiting the ability of HIV genes products to bind to the cytoplasmic domain of a CD4 receptor. This domain is necessary to the ability of the HIV Nef and Vpu gene products to connect the CD4 receptor to cellular degradation pathways. |
| 06/19/2008 | US20080146494 Glycoconjugation methods and proteins/peptides produced by the methods |
| 06/19/2008 | US20080146493 increasing Na ion transport and/or epithelial fluid transport in a vertebrate by administering an effective amount of haptoglobin or haptoglobin and hemoglobin. The invention also provides a new therapeutic approach for treating disorders associated with insufficient epithelial Na ion fluid transport |
| 06/19/2008 | US20080146492 Insulin production methods and pro-insulin constructs |
| 06/19/2008 | US20080146491 treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally, 1,25-dihydroxyvitamin D analogs can be used in combination with the calcitonin, calcitonin-like peptides or calcitonin |
| 06/19/2008 | US20080146490 Glp-1 Analogue Formulations |
| 06/19/2008 | US20080146489 Treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well. |
| 06/19/2008 | US20080146488 strongly immunogenic polypeptide to a more weakly immunogenic polypeptide can precipitate and focus a CpG adjuvant to increase in vivo priming of a cytotoxic T-lymphocyte (CTL) response, and thus increase the immunogenicity of the more weakly immunogenic polypeptide |
| 06/19/2008 | US20080145938 Buffer solution for electroporation and a method comprising the use of the same |
| 06/19/2008 | US20080145927 Stresscopins and their uses |
| 06/19/2008 | US20080145884 Sfrp and peptide motifs that interact with sfrp and methods of their use |
| 06/19/2008 | US20080145866 Modified human thymic stromal lymphopoietin |
| 06/19/2008 | US20080145859 Diagnosis and treatment of cancer |
| 06/19/2008 | US20080145855 Mutations in the Ferroportin 1 Gene Associated with Hereditary Haemochromatosis |
| 06/19/2008 | US20080145451 Composition for relieving discomfort |
| 06/19/2008 | US20080145449 Thiol reactive agents as a therapeutic modality |
| 06/19/2008 | US20080145441 Core of metal atoms of gold, silver or copper covalently linked to a carbohydrate group and to at least 20 ligands |
| 06/19/2008 | US20080145419 High viscosity liquid controlled delivery system and medical or surgical device |
| 06/19/2008 | US20080145412 Administering a carrier and a 10-30 amino acids-containing peptide which has an integrin binding motif and a glycosaminoglycan binding motif; contact with cells to stimulate by induction of fibroblast and transforming growth factors (FGF2, TGF beta) and fibronectin; high potency; well-tolerated; bandages |
| 06/19/2008 | US20080145411 Oxidized coenzyme Q10, a lysolecithin and an oil and fat where the weight ratio of the lysolecithin to the Q10 is >0.7: superior absorption; bioavailabiliry; stability; heat resistance; photostabiliy; food supplement; nutrients drugs; beverages; feet; pet food, cosmetics; nutraceuticals; soft capsules |
| 06/19/2008 | US20080145404 Methods and compositions for regenerating connective tissue |
| 06/19/2008 | US20080145397 Multi-formed collagenous biomaterial medical device |
| 06/19/2008 | US20080145396 Coated implantable medical device |
| 06/19/2008 | US20080145395 Multi-formed collagenous biomaterial medical device |
| 06/19/2008 | US20080145394 Coated implantable medical device |
| 06/19/2008 | US20080145386 TRPV1+ sensory neurons control of beta-cell stress and islet inflammation in diabetes |
| 06/19/2008 | US20080145383 Method for Solubilizing Peptide Mixtures |
| 06/19/2008 | US20080145382 (CTLA-4, Cytotoxic T-Lymphocyte Antigen-4); vaccines, feline immunomodulators, antitumor agents; treating feline viral diseases; veterinary medicine |
| 06/19/2008 | US20080145377 G-CSF Polypeptides And Uses Thereof |
| 06/19/2008 | US20080145372 Bioreductively-Activated Prodrugs |
| 06/19/2008 | US20080145370 Multimeric immunoglobulin for use in prevention and treatment of viral and microorganismal infection |
| 06/19/2008 | US20080145369 Using pc-cell-derived growth factor concentration as diagnostic indicator of cell proliferative disorders |
| 06/19/2008 | US20080145368 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| 06/19/2008 | US20080145366 Platelet derived growth factor specific immunoglobulin for use in diagnosis, prevention and treatment of cell proliferative disorders; antisense agents; antitumor agents |
| 06/19/2008 | US20080145365 Human and mammalian stem cell-derived neuron survival factors |
| 06/19/2008 | US20080145364 Method for High Throughput Screening for Anitbodies and Proteins Inducing Apoptosis |
| 06/19/2008 | US20080145361 Uses of mammalian cytokine; related reagents |
| 06/19/2008 | US20080145359 Imaging, diagnosis and treatment of disease |
| 06/19/2008 | US20080145358 Method for Determining Responsiveness to Chk1 Inhibitors |
| 06/19/2008 | US20080145357 Tissue fusion method using collagenase for repair of soft tissue |
| 06/19/2008 | US20080145356 Administering glutenase to Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides |
| 06/19/2008 | US20080145355 Formulations Including Monovalent Alginate to Enhance Effectiveness of Administered Digestive Enzymes |
| 06/19/2008 | US20080145354 Polyoxyethylene glycol; biocompatability; bioavailability |
| 06/19/2008 | US20080145352 Method for promoting axonal re-growth and behavior recovery in spinal cord injury |
| 06/19/2008 | US20080145351 Using protein kinase m-zeta inhibitor as therapeutic in treatment of alcohol addiction, post-traumatic disorder, and phobia |
| 06/19/2008 | US20080145350 Method Of Curl Retention In Hair And Lashes |
| 06/19/2008 | US20080145347 p-Hyde sequences in the Rat |
| 06/19/2008 | US20080145340 Neuroactive agents and methods of their use |
| 06/19/2008 | US20080145339 Modified rolling circle initiator protein for use as therapeutic tool in suppression of viral replication and disorders |
| 06/19/2008 | US20080145337 Using interferon gamma as constituent of therapeutic for prevention and treatment of arthritic and autoimmune disorders |
| 06/19/2008 | US20080145336 Use of isoindol-1-one or 1,3-dione compounds for treating cancer, angiogenesis inhibition or phosphodiesterase-4 inhibition; use with various other biodrugs and drugs |
| 06/19/2008 | US20080145335 Which protect neural cells from degeneration and/or death in response to injury or disease; hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease |
| 06/19/2008 | US20080145334 Hepatitis c virus inhibitors |
| 06/19/2008 | US20080145333 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients |
| 06/19/2008 | US20080143574 A-D converter, A-D convert method, and A-D convert program |
| 06/19/2008 | CA2707542A1 Casein-derived peptides having anxiolytic activity |
| 06/19/2008 | CA2677688A1 Vaccine for periodontitis and methods of use |
| 06/19/2008 | CA2672529A1 Porous keratin construct and method of making the same |
| 06/19/2008 | CA2672524A1 Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor |
| 06/19/2008 | CA2672490A1 Trpv1+ sensory neurons control of beta-cell stress and islet inflammation in diabetes |
| 06/19/2008 | CA2672406A1 Novel compounds and their effects on feeding behaviour |
| 06/19/2008 | CA2672297A1 Compositions and methods for treating pathologic angiogenesis and vascular permeability |
| 06/19/2008 | CA2672215A1 Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| 06/19/2008 | CA2672055A1 Treatment of cachexia |
| 06/19/2008 | CA2671971A1 Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof |
| 06/19/2008 | CA2671863A1 Method of treating acute renal failure with thrombomodulin variants |
| 06/19/2008 | CA2671736A1 Use of endos for the treatment or prevention of igg-mediated diseases and conditions |
| 06/19/2008 | CA2671724A1 Alpha b-crystallin as a therapy for inflammation |
| 06/19/2008 | CA2670054A1 Selective inhibitors of neurotensin degrading enzymes |
| 06/19/2008 | CA2669109A1 Il-17b for use in wound healing |
| 06/19/2008 | CA2668375A1 Composition for cartilage formation or repair comprising a nell based product |
| 06/19/2008 | CA2571645A1 Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture |